The Zhitong Finance App learned that Maiwei Bio-B (02493) rose more than 5% in the intraday period. As of press release, it had risen 2.63% to HK$21.06, with a turnover of HK$5.941 million.
According to the news, Maiwei Bio-B recently announced its 2026 interim results. The company's revenue was about 312 million yuan, up 209.06% year on year; gross profit was about 236 million yuan, up 198.67% year on year; and R&D costs were about 431 million yuan, up about 10% year on year. The increase in revenue was mainly due to the increase in external licensing revenue of Kalexo and Disc, and the increase in revenue due to the increase in sales revenue of Junmaikang® pharmaceuticals.
According to the announcement, the core product 9MW2821 has entered a critical clinical stage and obtained multiple breakthrough therapy certifications (BTD). Currently, four phase III key registered clinical trials are underway. Among them, the phase III clinical plan for urothelial carcinoma (UC) single drug and combination therapy, and cervical cancer (CC) single drug therapy is scheduled to be analyzed in 2026. It is expected that the results of this analysis will be submitted to a pre-marketing conference for the new drug.
Looking forward to the future, the company will accelerate the testing phase of the core product. Currently, the nectin-4 targeted ADC product 9mW2821, which is developed by the company itself, ranks first in the country and second in the world. It is also the world's first same-target drug to advance to stage III clinical registration of cervical cancer. Currently, the three core indications for urothelial cancer, combined immunotherapy, and cervical cancer are in the critical phase III clinical phase.